InMed Pharmaceuticals

$4.14
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.19 (-4.39%) Today
$0.00 (0.00%) As of 9:00 PM UTC after-hours

Why Robinhood?

You can buy or sell INM and other stocks, options, and ETFs commission-free!

About INM

InMed Pharmaceuticals, Inc. engages in the research and development of cannabinoid-based therapies and biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. It offers pipeline of medications that target diseases with unmet medical needs, such as epidermolysis bullosa, glaucoma, and orofacial pain. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada. The listed name for INM is InMed Pharmaceuticals Inc. Common Shares.

CEO
Eric A. Adams
Employees
—
Headquarters
Vancouver, British Columbia
Founded
1981
Market Cap
26.23M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
7.52K
High Today
$4.44
Low Today
$4.03
Open Price
$4.38
Volume
70.19K
52 Week High
$5.29
52 Week Low
$2.95

Collections

INM Earnings

-$0.41
-$0.27
-$0.14
$0.00
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
Expected Feb 5, Pre-Market

You May Also Like

GSLC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure